3rd December
2024
ANANDA
DEVELOPMENTS PLC
("Ananda"
or the "Company")
Key
Stability Testing Milestones Achieved for MRX1
Ananda Developments plc (AQSE: ANA),
a Company focused on the development of cannabidiol (CBD) based
therapies for the treatment of a range of complex inflammatory pain
conditions, is pleased to announce that its MRX1 CBD drug candidate
has successfully passed through a number of critical drug stability
timepoints ahead of its use in two Phase II and one Phase I
clinical studies.
The term 'drug stability' refers to
the extent to which a drug retains, within specified time limits
throughout its period of storage and use, acceptably comparable
properties and characteristics to that which it possessed at the
time of manufacture.
Highlights:
· Critical time
points for stability achieved, confirming MRX1 will remain stable
under standard conditions for the duration of the trials
· MRX1 now moves
towards the final set-up preparatory works ahead of its use in two
Phase II clinical trials for Chemotherapy Induced Peripheral
Neuropathy and Endometriosis, and a Phase I Pharmacokinetic
study
· For more
information & to view an additional video by Jeremy
Sturgess-Smith, Finance Director of Ananda Developments Plc, and
the chance to have your questions directly answered by the
management team, please head to our interactive investor hub
via: https://investors.anandadevelopments.com/link/7PlXJP
The stability data confirms that
MRX1 CBD drug candidate maintains its physical, chemical and
microbiological properties within the required parameters,
following the requirements of Good Manufacturing Practice
standards. These developments represent significant progress as
Ananda prepares to advance MRX1 into clinical trials.
Ananda's CEO,
Melissa Sturgess commented:
"Stability data ensures MRX1 will maintain its intended
quality, safety, and efficacy throughout the clinical trial. It is
not just a regulatory requirement but also critical to the
scientific integrity of our studies, ensuring reliable results and
protecting participant safety."
-Ends-
To stay up to date with the latest
developments at Ananda, we encourage you to follow our social media
channels which are:
· Investor
Hub: investors.anandadevelopments.com
· Instagram:
https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter:
https://twitter.com/AnandaPlc
· Investor Meet
Company:
https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
The Directors of the Company accept
responsibility for the contents of this
announcement.
|
ANANDA DEVELOPMENTS PLC
|
+44
(0)7463 686 497
|
|
|
ir@anandadevelopments.com
|
|
Chief Executive Officer
|
|
|
Melissa Sturgess
|
|
|
|
|
|
Finance Director
|
|
|
Jeremy
Sturgess-Smith
|
|
|
|
|
|
SP
ANGEL CORPORATE FINANCE LLP
|
+44 (0)20
3470 0470
|
|
|
|
|
Corporate Finance
|
|
|
Richard Morrison
|
|
|
Caroline Rowe
|
|
|
|
|
|
Corporate Broking
|
|
|
Abigail Wayne
|
|
|
Rob Rees
|
|
|
Yellow Jersey PR (media enquiries)
Sarah MacLeod
Charles Goodwin
Zara McKinlay
|
+44 (0)20
3004 9512
ananda@yellowjerseypr.com
|
About Ananda Developments
Ananda is an AQSE-listed
life sciences company focused on the research and
clinical development of CBD-based therapies for a range of complex
inflammatory pain conditions.
For more information, please
visit: https://anandadevelopments.com
Market Abuse Regulation (MAR)
Disclosure
The information contained within
this announcement is deemed by the Company to constitute inside
information. Upon the publication of this announcement via a
Regulatory Information Service, this inside information is now
considered to be in the public domain.
https://investors.anandadevelopments.com/link/7PlXJP